JPWO2023133485A5 - - Google Patents
Info
- Publication number
- JPWO2023133485A5 JPWO2023133485A5 JP2024540899A JP2024540899A JPWO2023133485A5 JP WO2023133485 A5 JPWO2023133485 A5 JP WO2023133485A5 JP 2024540899 A JP2024540899 A JP 2024540899A JP 2024540899 A JP2024540899 A JP 2024540899A JP WO2023133485 A5 JPWO2023133485 A5 JP WO2023133485A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- optionally
- pharmaceutical composition
- antigen
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266548P | 2022-01-07 | 2022-01-07 | |
| US63/266,548 | 2022-01-07 | ||
| PCT/US2023/060206 WO2023133485A2 (en) | 2022-01-07 | 2023-01-06 | Compositions and methods for treatment of thyroid eye disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503339A JP2025503339A (ja) | 2025-02-03 |
| JP2025503339A5 JP2025503339A5 (https=) | 2026-01-16 |
| JPWO2023133485A5 true JPWO2023133485A5 (https=) | 2026-01-16 |
Family
ID=87074297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540899A Pending JP2025503339A (ja) | 2022-01-07 | 2023-01-06 | 甲状腺眼疾患を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240360227A1 (https=) |
| EP (1) | EP4460524A4 (https=) |
| JP (1) | JP2025503339A (https=) |
| KR (1) | KR20240130134A (https=) |
| CN (1) | CN118679187A (https=) |
| AU (1) | AU2023205915A1 (https=) |
| MX (1) | MX2024008530A (https=) |
| WO (1) | WO2023133485A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| WO2025014774A1 (en) | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
| WO2025051229A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京拓界生物医药科技有限公司 | Igf-1r及tshr结合蛋白及其医药用途 |
| WO2025136985A1 (en) * | 2023-12-17 | 2025-06-26 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| WO2007062037A2 (en) * | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| WO2013169611A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
-
2023
- 2023-01-06 WO PCT/US2023/060206 patent/WO2023133485A2/en not_active Ceased
- 2023-01-06 JP JP2024540899A patent/JP2025503339A/ja active Pending
- 2023-01-06 KR KR1020247026159A patent/KR20240130134A/ko active Pending
- 2023-01-06 CN CN202380021098.6A patent/CN118679187A/zh active Pending
- 2023-01-06 MX MX2024008530A patent/MX2024008530A/es unknown
- 2023-01-06 AU AU2023205915A patent/AU2023205915A1/en active Pending
- 2023-01-06 EP EP23737768.4A patent/EP4460524A4/en active Pending
-
2024
- 2024-07-01 US US18/760,539 patent/US20240360227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250257127A1 (en) | Anti-DLL3 Antibodies and Uses Thereof | |
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2018527887A5 (https=) | ||
| US20250313639A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| CA3240723A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| JP2021534797A5 (https=) | ||
| EP4095158A1 (en) | Pharmaceutical composition containing anti-btla antibody and use thereof | |
| CA3140075A1 (en) | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof | |
| CN115698074A (zh) | 抗-cd98抗体和其用途 | |
| CN110612309A (zh) | 用于降低免疫原性的方法和组合物 | |
| JP2021525059A5 (https=) | ||
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| TW202342095A (zh) | 用於治療和預防ｃｏｖｉｄ—１９之組成物 | |
| US20250099583A1 (en) | Pharmaceutical compositions of anti-igf-1r antibodies | |
| CN119424632A (zh) | 治疗结直肠癌的联用药物组合物 | |
| JPWO2023122714A5 (https=) | ||
| JP2025003404A (ja) | 血液脳関門を通過するグラニュリンの送達のための化合物 | |
| AU2016294332A1 (en) | Treatment of pruritus | |
| JPWO2023133485A5 (https=) | ||
| JPWO2023133486A5 (https=) | ||
| JP2026062861A (ja) | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 | |
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| JPWO2022187510A5 (https=) | ||
| US20230203171A1 (en) | Aqueous pharmaceutical composition of levilimab | |
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |